GlassScriptPhysician profile
Mahtab Sohrevardi
NPI 1578777033
$4,927.21
in general payments reported to CMS, 2019-2025
26 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $505 · 2021: $925 · 2022: $412 · 2023: $185 · 2024: $1,366 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $1,036.77 | 2019-2025 | |
| Novo Nordisk INC | $729.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $673.99 | 2019-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $385.55 | 2021-2025 | Omnipod |
| Medtronic, INC. | $233.18 | 2024-2025 | Minimed 780g |
| Abbott Laboratories | $203.76 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $179.97 | 2024-2025 | Korlym |
| Lilly USA, LLC | $165.94 | 2019-2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $165.25 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $128.39 | 2024 | |
| Idorsia Pharmaceuticals US INC | $120.52 | 2023 | Quviviq |
| Recordati_rare_diseases_inc. | $106.26 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $106.16 | 2025 | Yorvipath, Skytrofa |
| Glaxosmithkline, LLC. | $90.21 | 2024 | Benlysta |
| Radius Health, INC. | $81.59 | 2019-2025 | Tymlos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $74.68 | 2024 | Cequr Simplicity |
| Beta Bionics, INC. | $72.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Neurocrine Biosciences, INC. | $66.20 | 2025 | |
| Xeris Pharmaceuticals, INC. | $62.85 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $62.02 | 2024 | |
| Tandem Diabetes Care, INC. | $61.73 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $44.55 | 2025 | |
| Madrigal Pharmaceuticals | $23.59 | 2024 | Resmetirom |
| Horizon Therapeutics Plc | $20.95 | 2023 | Tepezza |
| Lifescan, INC. | $18.95 | 2019 | |
| Ibsa Pharma INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahtab Sohrevardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.